Cryptococcal Meningitis - Pipeline Insight, 2024

This ''Cryptococcal Meningitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cryptococcal Meningitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cryptococcal Meningitis Understanding

Cryptococcosis is an important opportunistic infection that causes more than 100,000 HIV-related deaths each year. It was named the Busse-Buschke disease because of its first description by Otto Busse and Abraham Buschke in 1894.

Even though the infection is usually HIV-related, in many centers (especially in developed countries), most of the non-HIV-related cases include patients under immunosuppressive treatments or with organic failure syndromes, transplants, innate immunological problems, common variable immunodeficiency syndrome, and hematological disorders.

The organism is acquired by inhalation. After being deposited into the pulmonary alveoli, the yeast spores must survive the normal to high pH and the physiological concentrations of carbon dioxide before they are phagocytized by alveolar macrophages, a more acidic environment, and disseminated after a latent period of containment in the lung lymph nodes. The essential factor in the survival of C. neoformans in this extracellular environment is glucosylceramide synthase.

Cryptococcal Meningitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryptococcal Meningitis pipeline landscape is provided which includes the disease overview and Cryptococcal Meningitis treatment guidelines. The assessment part of the report embraces, in depth Cryptococcal Meningitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryptococcal Meningitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Cryptococcal Meningitis. The therapies under development are focused on novel approaches to treat/improve Cryptococcal Meningitis.

Cryptococcal Meningitis Emerging Drugs

ATI-2307: Appili Therapeutics
ATI-2307 is a novel clinical stage antifungal candidate. It has a highly differentiated mechanism of action and has demonstrated antifungal activity against multiple high priority and clinically important fungi, including Cryptococcus and multi-drug resistant Candida. ATI-2307 is undergoing rigorous preclinical evaluations to inform clinical development strategy and support initiation of Phase 2 development in 2022. Potential target indications include cryptococcal meningitis and invasive candidiasis.

Cryptococcal Meningitis: Therapeutic Assessment

This segment of the report provides insights about the Cryptococcal Meningitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cryptococcal Meningitis

There are approx. 5+ key companies which are developing the therapies Cryptococcal Meningitis. The companies which have their Cryptococcal Meningitis drug candidates in the most advanced stage, i.e phase II include Matinas Biopharma

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cryptococcal Meningitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cryptococcal Meningitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryptococcal Meningitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryptococcal Meningitis drugs.

Cryptococcal Meningitis Report Insights

• Cryptococcal Meningitis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cryptococcal Meningitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cryptococcal Meningitis drugs?
• How many Cryptococcal Meningitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryptococcal Meningitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cryptococcal Meningitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cryptococcal Meningitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mycovia
• Appili Therapeutics
• Matinas Biopharma
• Gilead Sciences

Key Products

• VT-1598
• ATI-2307
• MAT2203
• AmBisome

This product will be delivered within 2 business days.